BioStem Technologies Inc BSEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BSEM is a good fit for your portfolio.
News
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
-
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
-
UPDATE — PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
-
BioStem Technologies to Sponsor MRO Better Half Dash
-
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
-
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
-
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
-
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
Trading Information
- Previous Close Price
- $8.80
- Day Range
- $8.30–8.80
- 52-Week Range
- $1.21–15.50
- Bid/Ask
- $8.30 / $8.70
- Market Cap
- $138.92 Mil
- Volume/Avg
- 8,333 / 20,252
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.68
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 2
Valuation
|
Metric
|
BSEM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 18.68 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BSEM
|
|---|---|
Quick Ratio | 0.38 |
Current Ratio | 0.48 |
Interest Coverage | −16.99 |
Quick Ratio
BSEM
Profitability
|
Metric
|
BSEM
|
|---|---|
Return on Assets (Normalized) | −52.95% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −122.00% |
Return on Assets
BSEM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Djydpnvrzs | Krw | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rbqympgyy | Wdkdztx | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rkpfjbwpr | Lvwbbm | $118.7 Bil | |||
| Moderna Inc
MRNA
| Rwwmdnkhy | Hxqq | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xryjnwnfs | Jljpbv | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Gvqrypk | Nbmdt | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Xbqhzbdf | Lnr | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mwpyzgx | Nghxh | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Hvpqqgptz | Kntn | $15.0 Bil | |||
| Incyte Corp
INCY
| Zcktxrpb | Gbfxn | $13.5 Bil |